Aptevo Therapeutics (APVO) Invested Capital (2016 - 2023)
Historic Invested Capital for Aptevo Therapeutics (APVO) over the last 9 years, with Q3 2023 value amounting to $14.7 million.
- Aptevo Therapeutics' Invested Capital fell 1713.77% to $14.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was $14.7 million, marking a year-over-year decrease of 1713.77%. This contributed to the annual value of $20.0 million for FY2022, which is 5504.15% up from last year.
- Latest data reveals that Aptevo Therapeutics reported Invested Capital of $14.7 million as of Q3 2023, which was down 1713.77% from $16.3 million recorded in Q2 2023.
- Over the past 5 years, Aptevo Therapeutics' Invested Capital peaked at $39.5 million during Q3 2019, and registered a low of -$3.9 million during Q1 2022.
- Over the past 5 years, Aptevo Therapeutics' median Invested Capital value was $20.0 million (recorded in 2022), while the average stood at $19.7 million.
- In the last 5 years, Aptevo Therapeutics' Invested Capital skyrocketed by 73828.34% in 2021 and then plummeted by 11878.96% in 2022.
- Quarter analysis of 5 years shows Aptevo Therapeutics' Invested Capital stood at $31.7 million in 2019, then crashed by 31.89% to $21.6 million in 2020, then crashed by 40.34% to $12.9 million in 2021, then skyrocketed by 55.04% to $20.0 million in 2022, then decreased by 26.31% to $14.7 million in 2023.
- Its Invested Capital was $14.7 million in Q3 2023, compared to $16.3 million in Q2 2023 and $23.3 million in Q1 2023.